Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness

BACKGROUND: Vedolizumab (VDZ) is a humanized monoclonal IgG1 antibody which inhibits leukocyte vascular adhesion and migration into the gastrointestinal tract through α4β7 integrin blockade. AIMS: We retrospectively assessed the 12-month, real-world efficacy and safety of VDZ as induction and mainte...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Can Assoc Gastroenterol
Main Authors: Zezos, Petros, Kabakchiev, Boyko, Weizman, Adam V, Nguyen, Geoffrey C, Narula, Neeraj, Croitoru, Kenneth, Steinhart, A Hillary, Silverberg, Mark S
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2020
Fag:
Original Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7165264/
https://ncbi.nlm.nih.gov/pubmed/32328546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy065
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker